CompanyDrug

Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity

CompanyDrug

Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia

CompanyDrug

China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD

Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data
CompanyDrug

Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data

Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment
CompanyDrug

Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment

CompanyDrug

Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management

CompanyDrug

Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus

CompanyDeals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

CompanyDeals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Johnson & Johnson Reports Q2 2026 Results with 6.6% Sales Growth, Raises Full-Year Guidance
Company

Johnson & Johnson Reports Q2 2026 Results with 6.6% Sales Growth, Raises Full-Year Guidance

CompanyDeals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics